Patient-derived tumour xenografts as models for oncology drug development

Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Tentler, John J., Tan, Aik Choon, Weekes, Colin D., Jimeno, Antonio, Leong, Stephen, Pitts, Todd M., Arcaroli, John J., Messersmith, Wells A., Eckhardt, S. Gail
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3928688/
https://ncbi.nlm.nih.gov/pubmed/22508028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2012.61
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares